Clopidogrel response variability and its correlation with early recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention

Pharmacology

Volumn 87, Issue 5-6, 2011, Pages 321-330

  Liu, Yamin ^a,b   Liu, Naifeng ^b   Li, Weilan ^b   Shao, Hua ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Antiplatelet therapy; Clopidogrel; Percutaneous coronary intervention; Recurrent cardiovascular events

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; GLYCOPROTEIN IB; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHINESE; CORONARY STENT; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INDIVIDUALITY; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80955174480     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000324529     Document Type: Article

References (38)

1. Fei Y, Xiantao S, Hong L, Rui T, Xin C, Shuzheng L; Registry Of PCI In China (ROPIC) Study Investigators: Percutaneous coronary interventions in Chinese mainland 2008. Int J Cardiol 2010; 145: 314-315.
2. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, Ikeda T, Yamamoto H, Akao M, Furukawa Y, Shizuta S, Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishimoto N, Ouchi C, Morimoto T, Kita T, Kimura T: Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary inter vention. Circ J 2009; 73: 336-342.
3. Gurbel PA, O'Connor CM, Cummings CC, Serebruany VL: Clopidogrel: the future choice for preventing platelet activation during coronary stenting? Pharmacol Res 1999; 40:107-111. (Pubitemid 29378089)
4. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533. (Pubitemid 32772726)
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
6. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG: Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 670S-707S. (Pubitemid 351892975)
7. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671-719.
8. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1598-1660.
9. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787. (Pubitemid 36603418)
10. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913. (Pubitemid 36736631)
11. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910. (Pubitemid 39452607)
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, Stranieri C, Trabetti E, Pignatti PF, Macaya C: PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15:89-93. (Pubitemid 38534691)
13. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396. (Pubitemid 40615608)
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49:1505-1516. (Pubitemid 46517957)
15. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the gold (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103:2572-2578. (Pubitemid 32521967)
16. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ: Cytochrome P450 2C19 681G 1 A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934. (Pubitemid 351636443)
17. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
18. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
19. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N: Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
20. Ruggeri ZM: New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994; 31:229-239. (Pubitemid 24229688)
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, Banuelos C, Macaya C: Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol 2004; 16:325-329. (Pubitemid 38715816)
22. O'Connor CM, Gurbel PA, Serebruany VL: Usefulness of soluble and surface-bound Pselectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999; 83: 1345-1349. (Pubitemid 29205744)
23. Serebruany VL, Atar D: Assessment of bleeding events in clinical trials - proposal of a new classification. Am J Cardiol 2007; 99: 288-290. (Pubitemid 46072771)
24. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834. (Pubitemid 350007957)
25. Shim CY, Yoon SJ, Park S, Kim JS, Choi JR, Ko YG, Choi D, Ha JW, Jang Y, Chung N, Shim WH, Cho SY: The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009; 134: 351-355.
26. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occu rrence (PRONTO) trial. Am Heart J 2003; 145: 239-247. (Pubitemid 36207944)
27. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750. (Pubitemid 44648629)
28. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45:1157-1164. (Pubitemid 40523131)
29. Angiolillo DJ: Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103:27A-34A.
30. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247. (Pubitemid 44497506)
31. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
32. Fontana P, Hulot JS, De Moerloose P, Gaussem P: Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007; 5:2153-2155. (Pubitemid 47450038)
33. Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, Huczek Z, Ploski R, Opolski G: Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008; 72:1165-1169. (Pubitemid 351957086)
34. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC: Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101:1088-1093.
35. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
36. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, Morath T, Schomig A, Kastrati A, von Beckerath N: Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
37. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF: Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103:806-811.
38. Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, Wang LS, Liu ZQ, Zhou HH: Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin Exp Pharmacol Physiol 2008; 35: 904-908. (Pubitemid 351953054)